Cancer gene suppression strategies: Issues and potential

Current Issues in Molecular Biology

Volumn 6, Issue 2, 2004, Pages 89-102

  Passioura, T ^a   Symonds, G ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOZYME; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; BCR ABL PROTEIN; DACARBAZINE; DEOXYRIBOZYME; DOUBLE STRANDED RNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; GLYCOPROTEIN P; HERZYME; IMATINIB; ISIS 3521; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; NUCLEIC ACID; OBLIMERSEN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN KINASE C ALPHA; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; RIBOZYME; RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GENETICS; CANCER INHIBITION; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEVER; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENE TARGETING; GENE TECHNOLOGY; GENETIC TRANSFECTION; HUMAN; HYPOTENSION; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MULTIPLE MYELOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOGENE; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; ONCOGENES; RNA INTERFERENCE; RNA, CATALYTIC;

EID: 1942531959     PISSN: 14673037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Agrawal, S., and Kandimalla, E.R. 2001. Antisense and/ or immunostimulatory oligonucleotide therapeutics. Curr. Cancer Drug Targets. 1:197-209.
2. Astriab-Fisher, A., Sergueev, D.S., Fisher, M., Shaw, B.R., and Juliano, R.L. 2000. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem. Pharmacol. 60: 83-90.
3. Audouy, S.A.L., de Leij, L.F.M.H., Hoekstra, D., and Molema, G. 2002. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm. Res. 19:1599-1605.
4. Bauerschmitz, G.J., Barker, S.D., and Hemminki, A. 2002. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents. Int. J. Oncol. 21:1161-1174.
5. Bramlage, B., Luzi, E., and Eckstein, F. 1998. Designing ribozymes for the inhibition of gene expresion. Trends in Biotech. 16: 434-438.
6. Branch, A.D., and Robertson, J.D. 1991. Efficient trans cleavage and a common structural motif for the ribozymes of the human hepatitis δ agent. Proc. Natl. Acad. Sci. USA. 88: 10163-10167.
7. Brown, M.D., Schatzlein, A.G., and Uchegbu, I.F. 2001. Gene delivery with synthetic (non viral) carriers. Int. J. Pharm. 229: 1-21.
8. Brummelkamp, T.R., Bernards, R., and Agami, R. 2002a. A system for stable expression of short interfering RNAs in mammalian cells. Science. 296: 550-553.
9. Brummelkamp, T.R., Bernards, R., and Agami, R. 2002b. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2:243-247.
10. Buchschacher, G.L. Jr. 2001. Introduction to retroviruses and retroviral vectors. Somat. Cell Mol. Genet. 26:1-11.
11. Buzayan, J.M., Hampel, A., and Bruening, F. 1986. Nucleotide sequence and newly formed phophodiester bond of spontaneously limaged satellite tobacco ringspot virus RNA. Nucleic Acids Res. 14: 9729-9743.
12. Cai, D.W., Mukhopadhyay, T., and Roth, J.A. 1995. Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther. 2:199-205.
13. Cairns, M.J., Saravolac, E.G., and Sun L.Q. 2002. Catalytic DNA: a novel tool for gene suppression. Curr. Drug Targets. 3:269-279.
14. Campos, L., Sabido, O., Rouault, J.P., and Guyotat, D. 1994. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood. 84:595-600.
15. Caplen, N.J., Parrish, S., Imani, F., Fire, A., and Morgan, R.A. 2001. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA. 98:9742-9747.
16. Carmeliet, P., and Jain, R.K. 2000. Angiogenesis in cancer and other diseases. Nature. 407: 249-257.
17. Castanotto, D., Li, J.R., Michienzi, A., Langlois, M.A., Lee, N.S., Puymirat, J., and Rossi, J.J. 2002. Intracellular ribozyme applications. Biochem. Soc. Trans. 30:1140-1145.
18. Cech, T.R., Zaug, A. J. and Grobowzski, P.J. 1981. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: Involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell. 27:487-496.
19. Chang, E.H., Miller, P.S., Cushman, C., Devadas, K., Pirollo, K.F., Ts'o, P.O. and Yu, Z.P. 1991. Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry 30:8283-8286.
20. Chen, H.X., Marshall, J.L., Ness, E., Martin, R.R., Dvorchik, B., Rizvi, N., Marquis, J., McKinlay, M., Dahut, W. and Hawkins, M.J., 2000. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin. Cancer Res. 6:1259-1266.
21. Cheng, S.Y., Huang, H.J., Nagane, M., Ji, X.D., Wang, D., Shih, C.C., Arap, W., Huang, C.M., and Cavenee, W.K. 1996. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA 93:8502-8507.
22. Cioca, D.P., Aoki, Y., and Kiyosawa, K. 2003. RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther. 2003 10:125-133.
23. Coudert, B., Anthoney, A., Fiedler, W., Droz, J.P., Dieras, V., Borner, M., Smyth, J.F., Morant, R., de Vries, M.J., Roelvink, M., European Organization for Research and Treatment of Cancer (EORTC) and Fumoleau, P. 2001. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group Report. Eur. J. Cancer 37:2194-2198.
24. Corey, D.R. 2002. Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene. 21:631-637.
25. Cory, S., and Adams, J.M. 2002. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer. 2: 647-656.
26. Crooke, S.T., 1999. Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta. 1489:31-44.
27. Dang, T., Johnson, D., Kelly, K., Rizvi, N., Holmlund, J. and Dorr, A. 2001. Multicenter phase II trial of an antisense inhibitor of H-ras (ISIS-2503) in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20: 332a.
28. Dass, C.R. 2002. Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo. J. Pharm. Pharmacol. 54:593-601.
29. Dass, C.R., Saravolac E.G., Li, Y., and Sun L.Q. 2002. Cellular uptake, distribution, and stability of 10-23 deoxyribozymes. Antisense Nucleic Acid Drug Dev. 12: 289-299.
30. Dean, N., McKay, R., Miraglia, L., Howard, R., Cooper, S., Giddings, J., Nicklin, P., Meister, L., Ziel, R., Geiger, T., Muller, M. and Fabbro, D. 1996. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-expression. Cancer Res. 56:3499-3507.
31. Dolnikov, A., King, A., Luxford, C., Symonds, G., and Sun, L.Q. 1996. Ribozyme-mediated suppression of v-myc expression abrogates apoptosis in transformed monocytes. Cancer Gene Ther. 3:289-295.
32. Dolnikov, A., Millington, M., Sun, L-Q., and Symonds, G. 2000. Induced p21WAF1 expression acts to reverse myc myelomonocytic cell transformation. Cancer Gene Ther. 7:1491-1503.
33. Dolnikov, A., Shen, S., Millington, M., Passioura, T., Pedler, M., Rasko, J.E.J., and Symonds, G. 2003. A sensitive dual fluorescence reporter system enables positive selection of ras suppressors by suppression of ras-induced apoptosis. Cancer Gene Ther. In Press.
34. Druker, B.J., Sawyers, C.L., Capdeville, R., Ford, J.M., Baccarani, M., and Goldman, J.M. 2001a. Chronic myelogenous leukemia. Hematology (Am. Soc. Hematol. Educ. Program). 87-112.
35. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R., and Talpaz, M. 2001b. Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. N. Engl. J. Med. 344:1038-1042.
36. Druker, B.J., Talpaz, M., Resta D.J., Peng, B., Buchdinger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C.L. 2001c. Efficacy and safetey of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031-1037.
37. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494-498.
38. Elbashir, S.M., Harborth, J., Weber, K., and Tuschl, T. 2002. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods. 26:199-213.
39. Forster, A.C., and Symons, R.H. 1987. Self-cleavage of plus and minus RNAs of a virusoid and structural model for the active sites. Cell. 49:211-220.
40. Gorre, M.E., Mohammad, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., and Sawyers, C.L. 2001. Clinical resistance to STI-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science. 293:876-880.
41. Guang Liu, W., and De Yao, K. 2002. Chitosan and its derivatives - a promising non-viral vector for gene transfection. J. Control Release. 83: 1-11.
42. Guerrier-Takada, C., Gardiner, K., Marsh, T., Pace, N., and Altman, S. 1983. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell. 35:849-857.
43. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
44. Haseloff, J., and Gerlach, W.L. 1988. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature. 334:585-591.
45. Hua, J., and Muschel, R.J. 1996. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 56:5279-5284.
46. Hutchins, C.J., Rathjen, P.D., Forster, A.C., and Symons, R.H. 1986. Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Acids Res. 14:3627-3640.
47. Jackson, J.K., Liang, L.S., Hunter, W.L., Reynolds, M., Sandberg, J.A., Springate, C., and Burt, H.M. 2002. The encapsulation of ribozymes in biodegradable polymeric matrices. Int. J. Pharm. 243: 43-55.
48. Jansen, B., Schlagbauer-Wadl, H., Brown, B.D., Bryan, R.N., van Elsas, A., Muller, M., Wolff, K., Eichler, H.G., and Pehamberger, H. 1998. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4:232-234.
49. Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wadl, H., Hoeller, C., Lucas, T., Hoermann, M., Hollenstein, U., Wolff, K., and Pehamberger, H. 2000. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet. 356:1728-1733.
50. Juhl, H., Downing, S.G., Wellstein, A., and Czubayko, F. 1997. HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting. J. Biol. Chem. 272:29482-29486.
51. Kachigian, L.M. 2000. Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. J. Clin. Investigation. 106:1189-1195.
52. Kanazawa, Y., Ohkawa, K., Ueda, K., Mira, E., Takehara, T., Sasaki, Y., Kasahara, A., and Hayashi, N. 1996. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 225:570-576.
53. Kashani-Sabat, M., Funato, T., Tone, T., Jiao, L., Wang, W., Yoshida, E., Kashfinn, B.I., Shitara, T., Wu, A.M., Moreno, J.G., Traweek, S.T., Ahlering, T.E., and Scanlon K.J. 1992. Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res. Dev. 2:3-15.
54. Kern, S.E., Pietenpol, J.A., Thiagalingam, S., Seymour, A., Kinzler, K.W., and Vogelstein, B. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 256:827-830.
55. Klapper, L.N., Kirschbaum, M.H., Sela, M. and Yarden, Y. 2000. Biochemical and clinical implications of the ErbB/ HER signaling network of growth factor receptors. Adv. Cancer Res. 77:25-79.
56. Klasa, R.J., Bally, M.B., Ng, R., Goldie, J.H., Gascoyne, R.D., and Wong, F.M. 2000. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin. Cancer Res. 6:2492-2500.
57. Konopleva, M., Tari, A.M., Estrov, Z., Harris, D., Xie, Z., Zhao, S., Lopez-Berestein, G., and Andreeff, M. 2000. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 95:3929-3938.
58. Kosciolek, B.A., Kalantidis, K., Tabler, M., and Rowley, P.T. 2003. Inhibition of telomerase activity in human cancer cells by RNA interference. Mol. Cancer Ther. 2: 209-216.
59. Kruger, K., Grabowski, P.J., Zaug, A.J., Sands, J., Gottschling, D.E., and Cech, T.R. 1982. Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell.31:147-157.
60. Kumar, P.K.R., and Ellington, A.D. 1995. Artificial evolution and natural ribozymes. FASEB J. 9:1183-1195.
61. Leirdal, M., and Sioud, M. 2002. Gene silencing in mammalian cells by preformed small RNA duplexes. Biochem. Biophys. Res. Commun. 295:744-748.
62. Lewis, D.L., Hagstrom, J.E., Loomis, A.G., Wolff, J.A., and Herweijer, H. 2002. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 2002 32:107-108.
63. Lewis, D.L., Hagstrom, J.E., Loomis, A.G., Wolff, J.A., and Werweijer, H. 2002. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32:107-108.
64. Luzi, E., Papucci, L., Schiavone, N., Donnini, M., Lapucci, A., Tempestini, A., Witort, E., Nicolin, A., and Capaccioli, S. 2003. Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modified, synthetic ribozyme. Cancer Gene Ther. 10:201-208.
65. Lynch, T.J., Raju, R., Lind, M., Riviere, A., Gatzemeier, U., Drorr, A., Holmlund, J., Yuen, A., and Sikic, B. 2003. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report. Proc. Am. Soc. Clin. Oncol. 22:623.
66. Marcucci, G., Byrd, J.C., Dai, G., Klisovic, M.I., Kourlas, P.J., Young, D.C., Cataland, S.R., Fisher, D.B., Lucas, D., Chan, K.K., Porcu, P., Lin, Z-P., Farag, S.F., Frankel, S.R., Zweibel, J.A., Kraut, E.H., Balcerzak, S.P., Bloomfield, C.D., Grever, M.R., and Caligiuri, M.A. 2003. Phase 1 and pharmacodynamic studies of G3139, a bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 101:425-432.
67. Martinez, L.A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchenio, T., Lozano, G., and Harel-Bellan, A. 2002. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc. Natl. Acad. Sci. USA. 99:14849-14854.
68. Matsushita, H., Kobayashi, H., Mori, S., Kizaki, M., and Ikeda, Y. 1995. Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8;21). Biochem Biophys Res Commun. 215:431-437.
69. McCaffrey, A.P., Meuse, L., Pham, T.T., Conklin, D.S., Hannon, G.J., and Kay, M.A. 2002. RNA interference in adult mice. Nature. 418:38-39.
70. Medina, M.F., and Joshi, S. 1999. RNA-polymerase III-driven expression cassettes in human gene therapy. Curr. Opin. Mol. Ther. 1:580-594.
71. Meye, A., Wurl, P., Bache, M., Bartel, F., Grunbaum, U., Mansa-ard, J., Schmidt, H., and Taubert, H. 2000. Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene. Cancer Lett. 149:181-188.
72. Michael, D., and Oren, M. 2002. The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12:53-59.
73. Monia, B.P., Johnston, J.F., Geiger, T., Muller, M. and Fabbro, D. 1996. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2:668-675.
74. Nagy, P., Arndt-Jovin, D.J., and Jovin, T.M. 2003. Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. Exp. Cell Res. 285:39-49.
75. Nason-Burchenal, K., Allopenna, J., Begue, A., Stehelin, D., Dmitrovsky, E., and Martin, P. 1998. Targeting of PML/ RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells. Blood. 92:1758-1767.
76. Nemunaitis, J., Cunningham, C., Tong, A.W., Post, L., Netto, G., Paulson, A.S., Rich, D., Blackburn, A., Sands, B., Gibson, B., Randlev, B., and Freeman, S. 2003. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther. 10:341-352.
77. Nielsen L.L., and Maneval, D.C. 1998. p53 tumour suppressor gene therapy for cancer. Cancer Gene Ther. 5:52-63.
78. Paddison, P.J., Caudy, A.A., Bernstein, E., Hannon, G.J., and Conklin D.S. 2002. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16:948-958.
79. Paddison, P.J., and Hannon, G.J. 2002. RNA interference: the new somatic cell genetics?. Cancer Cell. 2:17-23.
80. Parry, T.J., Cushman, C., Gallegos, A.M., Agrawal, A.B., Richardson, M., Andrews, L.E., Maloney, L., Mokler, V.R., Wincott, F.E., and Pavco, P.A. 1999. Bioactivity of antiangiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Res. 27:2569-2577.
81. Pavco, P.A., Bouhana, K.S., Gallegos, A.M., Agrawal, A., Blanchard, K.S., Grimm, S.L., Jensen, K.L., Andrews, L.E., Wincott, F.E., Pitot, P.A., Tressler, R.J., Cushman, C., Reynolds, M.A., and Parry, T.J. 2000. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res. 6:2094-2103.
82. Pfeifer, A., and Verma, I.M. 2001. Gene therapy: promises and problems. Annu. Rev. Genomics Hum. Genet. 2:177-211.
83. Pirollo, K.F., Rait, A., Sleer, L.S., and Chang, E.H. 2003. Antisense therapeutics: from theory to clinical practice. Pharmacol. Ther. 99:55-77.
84. Quinonez, R., and Sutton R.E. 2002. Lentiviral vectors for gene delivery into cells. DNA Cell Biol. 21:937-951.
85. Rait, A., Krygier, J.E., Pirollo, K.F. and Chang, E.H. 1999. Sensitization of breast cancer cells to taxol by antisense HER-2 oligonucleotides. Antisense Nucleic Acid Drug Dev. 9:403-408.
86. Rapozzi, V., Burm, B.E., Cogoi, S., van der Marel, G.A., van Boom, J.H., Quadrifoglio, F., and Xodo, L.E. 2002. Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids. Nucleic Acids Res. 30:3712-3721.
87. St George, J.A. 2003. Gene therapy progress and prospects: adenoviral vectors. Gene Ther. 10:1135-1141.
88. Sanceau, J., Truchet, S., and Bauvois, B. 2003. Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in ewing sarcoma cells. J. Biol. Chem. In Press.
89. Sandberg, J.A., Bouhana, K.S., Gallegos, A.M., Agrawal, A.B., Grimm, S.L., Wincott, F.E., Reynolds, M.A., Pavco, P.A., and Parry T.J. 1999. Pharmocokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse. Antisense Nucleic Acid Drug Dev. 9:271-277.
90. Sandberg, J.A., Parker, V.P., Blanchard, K.S., Sweedler, D., Powell, J.A., Kachensky, A., Bellon, L., Usman, N., Rossing, T., Borden, E., and Blatt, L.M. 2000. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J. Clin. Pharmacol. 40:1462-1469.
91. Santoro, S.W., and Joyce, G.F. 1997. A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. U S A. 94:4262-4266.
92. Scanlon, K.J., Ishida, H., and Kashani-Sabet, M. 1994. Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc. Natl. Acad. Sci. USA. 91:11123-7.
93. Scherr, M., Grez, M., Ganser, A., and Engels, J.W. 1997. Specific hammerhead ribozyme-mediated cleavage of mutant N-ras mRNA in vitro and ex vivo. J. Biol. Chem. 272:14304-14313.
94. Scherr, M., Maurer, A.B., Klein, S., Ganser, A., Engels, J.W., and Grez, M. 1998. Effective reversal of a transformed phenotype by retrovirus-mediated transfer of a ribozyme directed against mutant N-ras. Gene Therapy. 5:1227-1234.
95. Scherr, M., Battmer, K., Winkler, T., Heidenreich, O., Ganser, A., and Eder, M. 2002. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood. 101:1566-1569.
96. Schlagbauer-Wadl, H., Klosner, G., Heere-Ress, E., Waltering, S., Moll, I., Wolff, K., Pehamberger, H., and Jansen, B. 2000. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J. Invest. Dermatol. 114: 725-730.
97. Semizarov, D., Frost, L., Sarthy, A., Kroeger, P., Halbert, DN., and Fesik, S.W. 2003. Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl. Acad. Sci. USA. 100:6347-6352.
98. Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J., and Sawyers, C.L. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:117-125.
99. Shay, J.W., and Wright, W.E. 2002. Telomerase: a target for cancer therapeutics. Cancer Cell. 2:257-265.
100. Shen, C., Buck, A., Liu, X., Winkler, M., and Reske, S.N. 2003. Gene silencing by adenovirus-delivered siRNA. FEBS lett. 539:111-114.
101. Shounan, Y., MacKenzie, K., Dolnikov, A., Miller, M., and Symonds, G. 1997. Myeloproliferative disease and myelodysplastic syndrome induced by transplantation of bone marrow cells expressing mutant p53. Leukemia. 11:1641-1649.
102. Shounan, Y., Dolnikov, A., MacKenzie, K.L., Chan, Y-Y., and Symonds, G. 1996. Retroviral transduction of hematopoietic progenitor cells with mutant p53 promotes survival and proliferation, modifies differentiation potential and inhibits apoptosis. Leukemia. 10:1619-1628.
103. Sioud, M., and Leirdal, M., 2000. Design of nuclease resistant protein kinase C-alpha DNA enzymes with potential tharapeutic application. J. Mol. Biol. 296:937-947.
104. Sioud, M., and Sorensen, D.R. 1998. A nuclease-resistant protein kinase C alpha ribozyme blocks glioma cell growth. Nat. Biotechnol. 16:556-561.
105. Snyder, D.S., Wu, Y., Wang, J.L., Rossi, J.J., Swiderski, P., Kaplan, B.E., and Forman, S.J. 1993. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood. 82:600-605.
106. Song, E., Lee, S.-K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., and Lieberman, J. 2003. RNA interference targeting Fas protects mice form fulminant hepatitis. Nat. Med. 9:347-351.
107. Spessotto, P., Rossi, F.M., Degan, M., Di Francia, R., Perris, R., Colombatti, A., and Gattei, V. 2002. Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. J. Cell Biol. 158:1133-1144.
108. Sun, L.Q., Cairns, M.J., Gerlach, W.L., Witherington, C., Wang, L., and King, A. 1999. Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving deoxyribozyme. J. Biol. Chem. 274:17236-17241.
109. Tanabe, T., Kuwabara, T., Warashina, M., Tani, K., Taira, K., and Asano, S. 2000. Oncogene inactivation in a mouse model. Nature. 406:473-474.
110. Tortora, G., Caputo, R., Damiano, V., Bianco, R., Chen, J., Agrawal, S., Bianco, A.R., and Ciardiello, F. 2000. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int. J. Cancer. 88: 804-809.
111. Uhlenbeck, O.C. 1987. A small catalytic oligoribonucleotide. Nature. 328:596-600.
112. van de Donk, N.W.C.J., Kamphuis, M.M.J., van Dijk, M., Borst, H.P.E., Bloem, A.C., and Lokhurst, H.M. 2003. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of bcl-2 protein. Leukemia. 17:211-219.
113. Wang, H., Nan, L., Yu, D., Agrawal, S., and Zhang, R. 2001. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res. 7:3613-3624.
114. Warashina, M., Kuwabara, T., Nakamatsu, T., and Taira, K. 1999. Extremely high and specific activity of DNA enzymes in cells with a philadelphia chromosome. Chem. Biol. 6:237-250.
115. Watanabe, T., and Sullenger, B.A. 2000 Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc. Natl. Acad. Sci. USA. 97:8490-8494.
116. Waters, J.S., Webb, A., Cunningham, D., Clarke, P.A., Raynaud, F., di Stefano, F., and Cotter, F.E. 2000. Phase I Clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-hodgkin's lymphoma. J. Clin. Oncol. 18:1812-1823.
117. Wilda, M., Fuchs, U., Wössmann, W., and Borkhardt, A. 2002. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene. 21:5716-5724.
118. Wohlbold L., van der Kuip, H., Miething, C., Vornlocher, H-P., Knabbe, C., Duyster, J., and Aulitzky, W.E. 2003. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood. In Press.
119. Wu, H., Hait, W.N., and Yang, J-M. 2003. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 63:1515-1519.
120. Yokoyama, Y., Takahashi, Y., Shinohara, A., Lian, Z., Wan, X., Niwa, K., and Tamaya, T. 1998. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res. 58:5406-5410.
121. Yuen, A., Halsey, J., Fisher, G., Advani, R., Moore, M., Saleh, M., Ritch, P., Harker, G., Ahmed, F., Jones, C., Polikoff, J., Keiser, W., Kwoh, T., Holmlund, J., Dorr, A. and Sikic, B., 2001. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:309a.
122. Zhang, L., Yang, N., Mohamed-Hadley, A., Rubin, S.C., and Coukos, G. 2003. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem. Biophys. Res. Commun. 303:1169-1178.
123. Ziegler, A., Luedke, G.H., Fabbro, D., Altmann, K.H., Stahel, R.A., and Zangemeister-Wittke, U. 1997. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J. Natl. Cancer Inst. 89:1027-1036.
124. Zoumadakis, M., and Tabler, M. 1995. Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes. Nucleic Acids Res. 23:1192-96.